Amplia Therapeutics Achieves Rare Complete Response in Pancreatic Cancer Trial

Amplia Therapeutics ( (AU:ATX) ) just unveiled an update.

Amplia Therapeutics has announced a significant milestone in its ACCENT clinical trial, where a patient with advanced pancreatic cancer achieved a pathological complete response (pCR) after treatment with their FAK inhibitor, narmafotinib, combined with chemotherapy. This rare outcome, indicating no signs of cancer in examined tissues, underscores the potential efficacy of narmafotinib in treating metastatic pancreatic cancer, potentially enhancing Amplia’s position in the oncology field and offering hope for improved patient outcomes.

More about Amplia Therapeutics

Amplia Therapeutics Limited is an Australian pharmaceutical company focusing on developing Focal Adhesion Kinase (FAK) inhibitors for treating cancer and fibrosis. The company is particularly focused on fibrotic cancers such as pancreatic and ovarian cancer, with FAK being a significant target in cancer treatment and chronic diseases like idiopathic pulmonary fibrosis.

YTD Price Performance: -35.96%

Average Trading Volume: 1,859,630

Technical Sentiment Signal: Sell

Current Market Cap: A$22.11M

For detailed information about ATX stock, go to TipRanks’ Stock Analysis page.